Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

PGC-1alpha Is Involved in the Pathogenesis of the Blunted Antioxidant Response in Friedreich[apos]s Ataxia and Is a Potential Therapeutic Target
Neurogenetics and Gene Therapy
(-)
004
Authors/Disclosures
Massimo Pandolfo, MD, FAAN (Montreal Neurological Institute/Hospital) Dr. Pandolfo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Minoryx. Dr. Pandolfo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Design Therapeutics . Dr. Pandolfo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Reata. Dr. Pandolfo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biomarin. Dr. Pandolfo has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Design Therapeutics. Dr. Pandolfo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Larimar. Dr. Pandolfo has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Genetics. Dr. Pandolfo has stock in Voyager Therapeutics. The institution of Dr. Pandolfo has received research support from Freidreich Ataxaia Research Alliance. Dr. Pandolfo has a non-compensated relationship as a Scientific Advisory Board with Friedreich Ataxia Research Alliance that is relevant to AAN interests or activities. Dr. Pandolfo has a non-compensated relationship as a Member-Meeting Management Committee with AAN that is relevant to AAN interests or activities.
Mario Manto, MD, PhD (ULB, Dept of Neurology) No disclosure on file
David Russell, MD (University of Oslo) No disclosure on file
No disclosure on file
No disclosure on file